Antiviral drug resistance: Mechanisms and clinical implications

Infectious Disease Clinics of North America

Volumn 24, Issue 3, 2010, Pages 809-833

  Strasfeld, Lynne ^a   Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cytomegalovirus; Drug resistance; Hepatitis B virus; Herpes simplex virus; Transplant; Varicella zoster virus

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HEPATITIS B ANTIBODY; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; LEFLUNOMIDE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PENCICLOVIR; RAPAMYCIN; TELBIVUDINE; TENOFOVIR; TOMEGLOVIR; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIDARABINE;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ELECTROLYTE DISTURBANCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VARICELLA ZOSTER VIRUS; VIRAL SKIN DISEASE; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; TIME; VIRUS;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; TIME FACTORS; VIRUSES;

EID: 77955251899     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.07.001     Document Type: Review

References (198)

1. Elion G.B., Furman P.A., Fyfe J.A., et al. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977, 74(12):5716-5720.
2. Elion G.B. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol 1993, 41(Suppl 1):2-6.
3. Gilbert C., Bestman-Smith J., Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002, 5(2):88-114.
4. Wagstaff A.J., Faulds D., Goa K.L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47(1):153-205.
5. Haefeli W.E., Schoenenberger R.A., Weiss P., et al. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med 1993, 94(2):212-215.
6. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999, 340(19):1462-1470.
7. Ormrod D., Scott L.J., Perry C.M. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000, 59(4):839-863.
8. Kalil A.C., Freifeld A.G., Lyden E.R., et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009, 4(5):e5512.
9. Crumpacker C.S. Ganciclovir. N Engl J Med 1996, 335(10):721-729.
10. Wagstaff A.J., Bryson H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994, 48(2):199-226.
11. Deray G., Martinez F., Katlama C., et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989, 9(4):316-321.
12. Safrin S., Cherrington J., Jaffe H.S. Clinical uses of cidofovir. Rev Med Virol 1997, 7(3):145-156.
13. Lalezari J., Schacker T., Feinberg J., et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997, 176(4):892-898.
14. Landry M.L., Stanat S., Biron K., et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000, 44(3):688-692.
15. Wang YC., Kao C.L., Liu W.T., et al. A cell line that secretes inducibly a reporter protein for monitoring herpes simplex virus infection and drug susceptibility. J Med Virol 2002, 68(4):599-605.
16. Frobert E., Ooka T., Cortay J.C., et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005, 49(3):1055-1059.
17. Suzutani T., Saijo M., Nagamine M., et al. Rapid phenotypic characterization method for herpes simplex virus and varicella-zoster virus thymidine kinases to screen for acyclovir-resistant viral infection. J Clin Microbiol 2000, 38(5):1839-1844.
18. Burns W.H., Saral R., Santos G.W., et al. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet 1982, 1(8269):421-423.
19. Sibrack C.D., Gutman L.T., Wilfert C.M., et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 1982, 146(5):673-682.
20. Stranska R., Schuurman R., Nienhuis E., et al. Survey of acyclovir-resistant herpes simplex virus in The Netherlands: prevalence and characterization. J Clin Virol 2005, 32(1):7-18.
21. Nugier F., Colin J.N., Aymard M., et al. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992, 36(1):1-12.
22. Englund J.A., Zimmerman M.E., Swierkosz E.M., et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990, 112(6):416-422.
23. Christophers J., Clayton J., Craske J., et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998, 42(4):868-872.
24. Danve-Szatanek C., Aymard M., Thouvenot D., et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004, 42(1):242-249.
25. Chakrabarti S., Pillay D., Ratcliffe D., et al. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000, 181(6):2055-2058.
26. Malvy D., Treilhaud M., Bouee S., et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005, 41(3):320-326.
27. Coen D.M., Schaffer P.A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A 1980, 77(4):2265-2269.
28. Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003, 26(1):29-37.
29. Morfin F., Souillet G., Bilger K., et al. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000, 182(1):290-293.
30. Gaudreau A., Hill E., Balfour H.H., et al. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998, 178(2):297-303.
31. Bacon T.H., Levin M.J., Leary J.J., et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003, 16(1):114-128.
32. Ljungman P., Ellis M.N., Hackman R.C., et al. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990, 162(1):244-248.
33. Bestman-Smith J., Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003, 77(14):7820-7829.
34. Longerich T., Eisenbach C., Penzel R., et al. Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy. Liver Transpl 2005, 11(10):1289-1294.
35. Frangoul H., Wills M., Crossno C., et al. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant 2007, 11(8):942-944.
36. Chen Y., Scieux C., Garrait V., et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000, 31(4):927-935.
37. Coen D.M., Kosz-Vnenchak M., Jacobson J.G., et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 1989, 86(12):4736-4740.
38. Andrei G., Fiten P., Froeyen M., et al. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007, 12(5):719-732.
39. Coen D.M. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994, 2(12):481-485.
40. Griffiths A., Chen S.H., Horsburgh B.C., et al. Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency. J Virol 2003, 77(8):4703-4709.
41. Griffiths A., Link M.A., Furness C.L., et al. Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase. J Virol 2006, 80(13):6568-6574.
42. Wyles D.L., Patel A., Madinger N., et al. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin Infect Dis 2005, 41(5):676-680.
43. De Clercq E. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Antimicrob Chemother 1984, 14(Suppl A):85-95.
44. Safrin S., Crumpacker C., Chatis P., et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991, 325(8):551-555.
45. Martinez V., Molina J.M., Scieux C., et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2006, 119(5):e9-11.
46. Sims C.R., Thompson K., Chemaly R.F., et al. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis 2007, 9(3):256-259.
47. Biron K.K., Elion G.B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980, 18(3):443-447.
48. Boivin G., Edelman C.K., Pedneault L., et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994, 170(1):68-75.
49. Jacobson M.A., Berger T.G., Fikrig S., et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990, 112(3):187-191.
50. Saint-Leger E., Caumes E., Breton G., et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001, 33(12):2061-2067.
51. Breton G., Fillet A.M., Katlama C., et al. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis 1998, 27(6):1525-1527.
52. Crassard N., Souillet A.L., Morfin F., et al. Acyclovir-resistant varicella infection with atypical lesions in a non-HIV leukemic infant. Acta Paediatr 2000, 89(12):1497-1499.
53. Morfin F., Thouvenot D., De Turenne-Tessier M., et al. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999, 43(10):2412-2416.
54. Levin M.J., Dahl K.M., Weinberg A., et al. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003, 188(7):954-959.
55. Bryan C.J., Prichard M.N., Daily S., et al. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J 2008, 27(10):946-948.
56. Andrei G., De Clercq E., Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?. Antiviral Res 2004, 61(3):181-187.
57. Pahwa S., Biron K., Lim W., et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988, 260(19):2879-2882.
58. Linnemann C.C., Biron K.K., Hoppenjans W.G., et al. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 1990, 4(6):577-579.
59. Visse B., Huraux J.M., Fillet A.M. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 1999, 59(1):84-90.
60. Safrin S., Berger T.G., Gilson I., et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991, 115(1):19-21.
61. Visse B., Dumont B., Huraux J.M., et al. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998, 178(Suppl 1):S55-S57.
62. Schliefer K., Gumbel H.O., Rockstroh J.K., et al. Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis 1999, 29(3):684-685.
63. Snoeck R., Andrei G., De Clercq E. Novel agents for the therapy of varicella-zoster virus infections. Expert Opin Investig Drugs 2000, 9(8):1743-1751.
64. Kamiyama T., Kurokawa M., Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 2001, 82(Pt 11):2761-2765.
65. Reusser P., Cordonnier C., Einsele H., et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious diseases working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996, 17(5):813-817.
66. Laurenti L., Piccioni P., Cattani P., et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004, 89(10):1248-1252.
67. Erice A., Chou S., Biron K.K., et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989, 320(5):289-293.
68. Jabs D.A., Enger C., Dunn J.P., et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998, 177(3):770-773.
69. Jabs D.A., Enger C., Forman M., et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother 1998, 42(9):2240-2244.
70. Reddy A.J., Zaas A.K., Hanson K.E., et al. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant 2007, 26(12):1286-1292.
71. Li F., Kenyon K.W., Kirby K.A., et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007, 45(4):439-447.
72. Limaye A.P., Raghu G., Koelle D.M., et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185(1):20-27.
73. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000, 356(9230):645-649.
74. Bhorade S.M., Lurain N.S., Jordan A., et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002, 21(12):1274-1282.
75. Eid A.J., Arthurs S.K., Deziel P.J., et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008, 22(2):162-170.
76. Lurain N.S., Bhorade S.M., Pursell K.J., et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002, 186(6):760-768.
77. Isada C.M., Yen-Lieberman B., Lurain N.S., et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002, 4(4):189-194.
78. Kruger R.M., Shannon W.D., Arens M.Q., et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999, 68(9):1272-1279.
79. Limaye A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002, 35(7):866-872.
80. Marfori J.E., Exner M.M., Marousek G.I., et al. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007, 38(2):120-125.
81. Avery R.K., Bolwell B.J., Yen-Lieberman B., et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004, 34(12):1071-1075.
82. Erice A., Borrell N., Li W., et al. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998, 178(2):531-534.
83. Hamprecht K., Eckle T., Prix L., et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003, 187(1):139-143.
84. Julin J.E., van Burik J.H., Krivit W., et al. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transpl Infect Dis 2002, 4(4):201-206.
85. Seo S.K., Regan A., Cihlar T., et al. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin Infect Dis 2001, 33(9):e105-e108.
86. Springer K.L., Chou S., Li S., et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005, 43(1):208-213.
87. Eckle T., Lang P., Prix L., et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 2002, 30(7):433-439.
88. Prix L., Hamprecht K., Holzhuter B., et al. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J Infect Dis 1999, 180(2):491-495.
89. Scott G.M., Weinberg A., Rawlinson W.D., et al. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007, 51(1):89-94.
90. Rodriguez J., Casper K., Smallwood G., et al. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection. Liver Transpl 2007, 13(10):1396-1400.
91. Oshima K., Kanda Y., Kako S., et al. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol 2008, 80(10):1769-1775.
92. Chou S., Lurain N.S., Thompson K.D., et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003, 188(1):32-39.
93. Chou S., Marousek G., Guentzel S., et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997, 176(3):786-789.
94. Chou S., Marousek G., Li S., et al. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol 2008, 43(1):107-109.
95. Chou S., Marousek G., Parenti D.M., et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998, 178(2):526-530.
96. Chou S., Marousek G.I., Van Wechel L.C., et al. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007, 51(11):4160-4162.
97. Chou S., Miner R.C., Drew W.L. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000, 182(6):1765-1768.
98. Chou S., Waldemer R.H., Senters A.E., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002, 185(2):162-169.
99. Chou S., Van Wechel L.C., Lichy H.M., et al. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005, 49(7):2710-2715.
100. Prichard M.N., Gao N., Jairath S., et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999, 73(7):5663-5670.
101. Wolf D.G., Courcelle C.T., Prichard M.N., et al. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci U S A 2001, 98(4):1895-1900.
102. Smith I.L., Cherrington J.M., Jiles R.E., et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997, 176(1):69-77.
103. Boivin G., Goyette N., Gilbert C., et al. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005, 7(3-4):166-170.
104. Cytomegalovirus. Am J Transplant 2004, 4(Suppl 10):51-58.
105. West P., Schmiedeskamp M., Neeley H., et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2008, 10(2):129-132.
106. Ljungman P., Deliliers G.L., Platzbecker U., et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the European group for blood and marrow transplantation. Blood 2001, 97(2):388-392.
107. Drew W.L. Is combination antiviral therapy for CMV superior to monotherapy?. J Clin Virol 2006, 35(4):485-488.
108. Mylonakis E., Kallas W.M., Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002, 34(10):1337-1341.
109. Chou S., Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006, 50(10):3470-3472.
110. Drew W.L., Miner R.C., Marousek G.I., et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006, 37(2):124-127.
111. Chou S., Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007, 196(1):91-94.
112. Chou S., Marousek G.I., Senters A.E., et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004, 78(13):7124-7130.
113. Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008, 82(1):246-253.
114. Winston D.J., Young J.A., Pullarkat V., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111(11):5403-5410.
115. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir (MBV) for treatment of resistant or refractory cytomegalovirus (CMV) infection in transplant recipients [abstract V-1256]. In: Programs and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, September 12-15, 2009.
116. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008, 8(5):541-548.
117. Buerger I., Reefschlaeger J., Bender W., et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol 2001, 75(19):9077-9086.
118. Ciesla S.L., Trahan J., Wan W.B., et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003, 59(3):163-171.
119. Quenelle D.C., Collins D.J., Pettway L.R., et al. Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. Antiviral Res 2008, 79(2):133-135.
120. Quenelle D.C., Collins D.J., Wan W.B., et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48(2):404-412.
121. Kern E.R., Bidanset D.J., Hartline C.B., et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother 2004, 48(12):4745-4753.
122. Kern E.R., Kushner N.L., Hartline C.B., et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005, 49(3):1039-1045.
123. Webster A.C., Lee V.W., Chapman J.R., et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006, (2). CD004290.
124. Hill J.A., Hummel M., Starling R.C., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84(11):1436-1442.
125. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6(6):1377-1386.
126. Buchler M., Caillard S., Barbier S., et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007, 7(11):2522-2531.
127. Haririan A., Morawski K., West M.S., et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007, 21(4):466-471.
128. Demopoulos L., Polinsky M., Steele G., et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008, 40(5):1407-1410.
129. San Juan R., Aguado J.M., Lumbreras C., et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008, 47(7):875-882.
130. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004, 10(5):328-336.
131. Marty F.M., Bryar J., Browne S.K., et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110(2):490-500.
132. Waldman W.J., Knight D.A., Blinder L., et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999, 42(5-6):412-418.
133. Levi M.E., Mandava N., Chan L.K., et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006, 8(1):38-43.
134. Battiwalla M., Paplham P., Almyroudis N.G., et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007, 9(1):28-32.
135. Kaptein S.J., Efferth T., Leis M., et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006, 69(2):60-69.
136. Efferth T., Romero M.R., Wolf D.G., et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008, 47(6):804-811.
137. Shapira M.Y., Resnick I.B., Chou S., et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46(9):1455-1457.
138. Tung B.Y., Kowdley K.V. Hepatitis B and liver transplantation. Clin Infect Dis 2005, 41(10):1461-1466.
139. Marzano A., Salizzoni M., Debernardi-Venon W., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001, 34(6):903-910.
140. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38(6):1419-1427.
141. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13(3):349-360.
142. Wong D.K., Yuen M.F., Yuan H., et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004, 40(3):727-737.
143. Moraleda G., Saputelli J., Aldrich C.E., et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997, 71(12):9392-9399.
144. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6(12):1315-1341. [quiz: 286].
145. Lok A.S. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008, 14(Suppl 2):S8-S14.
146. Margeridon-Thermet S., Shulman N.S., Ahmed A., et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naïve patients. J Infect Dis 2009, 199(9):1275-1285.
147. Gripon P., Rumin S., Urban S., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002, 99(24):15655-15660.
148. Villet S., Billioud G., Pichoud C., et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136(1):168-176. e2.
149. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006, 26(2):171-180.
150. Yuen M.F., Fung J., Wong D.K., et al. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009, 9(4):256-264.
151. Fung S.K., Chae H.B., Fontana R.J., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44(2):283-290.
152. Lai C.L., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36(6):687-696.
153. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999, 30(5):1302-1306.
154. Litwin S., Toll E., Jilbert A.R., et al. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005, 34(Suppl 1):S96-S107.
155. Chang M.L., Chien R.N., Yeh C.T., et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005, 43(1):72-77.
156. Zoulim F., Poynard T., Degos F., et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006, 13(4):278-288.
157. Locarnini S., Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007, 12(Suppl 3):H15-H23.
158. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125(6):1714-1722.
159. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131(6):1743-1751.
160. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009, 49(5):1503-1514.
161. Nguyen M.H., Keeffe E.B. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009, 16(3):149-155.
162. Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136(2):486-495.
163. Lee Y.S., Suh D.J., Lim Y.S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43(6):1385-1391.
164. Das K., Xiong X., Yang H., et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001, 75(10):4771-4779.
165. Sharon A., Chu C.K. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008, 80(3):339-353.
166. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27(6):1670-1677.
167. Villet S., Pichoud C., Billioud G., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48(5):747-755.
168. Delaney W.E., Yang H., Westland C.E., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77(21):11833-11841.
169. Yang H., Qi X., Sabogal A., et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005, 10(5):625-633.
170. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125(2):292-297.
171. Fung S.K., Andreone P., Han S.H., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43(6):937-943.
172. Yang H., Westland C., Xiong S., et al. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004, 61(1):27-36.
173. Kobashi H., Fujioka S., Kawaguchi M., et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naïve chronic hepatitis B. Hepatol Int 2009, 3(2):403-410.
174. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48(9):3498-3507.
175. Langley D.R., Walsh A.W., Baldick C.J., et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007, 81(8):3992-4001.
176. Tenney D.J., Rose R.E., Baldick C.J., et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007, 51(3):902-911.
177. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359(23):2442-2455.
178. Sheldon J., Camino N., Rodes B., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10(6):727-734.
179. Delaney W.E., Ray A.S., Yang H., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006, 50(7):2471-2477.
180. Fung S, Mazzulli T, Sherman M, et al. Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B. In: Programs and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Disease (AASLD). San Francisco, October 31-November 4, 2008 [abstract: 880].
181. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28(2):585-589.
182. Gane E.J., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132(3):931-937.
183. Angus P.W., Patterson S.J., Strasser S.I., et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48(5):1460-1466.
184. Bock C.T., Tillmann H.L., Torresi J., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122(2):264-273.
185. Fournier C., Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007, 11(4):869-892. ix.
186. Lampertico P., Vigano M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42(6):1414-1419.
187. Fung J., Lai C.L., Yuen J.C., et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007, 12(1):41-46.
188. van Bommel F., Wunsche T., Mauss S., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40(6):1421-1425.
189. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130(7):2039-2049.
190. Seifer M., Patty A., Serra I., et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009, 81(2):147-155.
191. Villeneuve J.P., Durantel D., Durantel S., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003, 39(6):1085-1089.
192. Yim H.J., Hussain M., Liu Y., et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44(3):703-712.
193. Brunelle M.N., Jacquard A.C., Pichoud C., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41(6):1391-1398.
194. Fung S.K., Fontana R.J. Management of drug-resistant chronic hepatitis B. Clin Liver Dis 2006, 10(2):275-302. viii.
195. Trojan J., Stuermer M., Teuber G., et al. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?. Gut 2007, 56(3):436-437. [author reply: 37].
196. Yatsuji H., Hiraga N., Mori N., et al. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 2007, 79(12):1811-1817.
197. Villet S., Ollivet A., Pichoud C., et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007, 46(3):531-538.
198. Gish R.G., Trinh H., Leung N., et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005, 43(1):60-66.